New therapy concept for the treatment of corona infections, especially covid-19 infections
AssigneeMaria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh
InventorMichael PLOCH
Life of this patent
Estimating the term…
Abstract
The present invention relates to the medical-pharmaceutical field of therapy of viral infections or viral diseases caused by corona viruses, especially COVID-19; especially, the present invention relates to an active ingredient and a drug or medicament containing said active ingredient for use in such therapy.
Claims22
1-32. (canceled)
A method for the treatment of a COVID-19 infection,
- wherein the method comprises the step of administering to a patient suffering from a COVID-19 infection a pharmaceutically effective amount of a 1,8-cineole,
- wherein the 1,8-cineole is applied as a systemic dosage form which is resistant to gastric juice but soluble in the small intestine,
- wherein the 1,8-cineole is present as a pure substance, wherein the 1,8-cineole is present with a purity of at least 95 wt. %, based on the 1,8-cineole, and wherein the 1,8-cineole is free of other terpenes.
The method according to claim 5,
- wherein the physiologically acceptable excipient is selected from the group consisting of triglycerides of C6-C12-fatty acids.
A drug or medicament in the form an antiviral agent for the treatment of a COVID-19 infection,
- wherein the drug or medicament comprises a 1,8-cineole together with at least one physiologically acceptable excipient,
- wherein the 1,8-cineole is applied as a systemic dosage form which is resistant to gastric juice but soluble in the small intestine,
- wherein the drug or medicament contains the 1,8-cineole as a pure substance with a purity of at least 95 wt. %, based on the 1,8-cineole, and wherein the drug or medicament contains the 1,8-cineole free of other terpenes.
A pharmaceutical composition for the treatment of a COVID-19 infection,
- wherein the composition comprises a 1,8-cineole together with at least one physiologically acceptable excipient,
- wherein the 1,8-cineole is applied as a systemic dosage form which is resistant to gastric juice but soluble in the small intestine,
- wherein the composition contains the 1,8-cineole as a pure substance with a purity of at least 95 wt. %, based on the 1,8-cineole, and wherein the composition contains the 1,8-cineole free of other terpenes.
A pharmaceutical combination for the treatment of a COVID-19 infection, wherein the pharmaceutical combination comprises at least the following components (A) and (B):
- (A) a 1,8-cineole;
- and
- (B) at least one further active ingredient selected from the group consisting of (i) anti-inflammatory active ingredients, (ii) blood-thinning and anticoagulant active ingredients, (iii) antiviral active ingredients, (iv) cardiovascular active ingredients, and combinations thereof;
- wherein the 1,8-cineole is present as a systemic dosage form which is resistant to gastric juice but soluble in the small intestine,
- wherein the 1,8-cineole is present as a pure substance, wherein the 1,8-cineole is present with a purity of at least 95 wt. %, based on the 1,8-cineole, and wherein the 1,8-cineole is free of other terpenes.
Dependencies are inferred from the claim text.